SEC Form 4 · accession 0001907345-26-000003
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary K. Lee
Officer — Chief Scientific Officer
Period of report
May 11, 2026
Accepted (ET)
Jun 15, 2026 · 6:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | May 11, 2026 | S | 130 | $18.92 | D | 17,808 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
- F2The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- F3Includes 1,000 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan.